XML Financial LLC Has $796,000 Stock Position in GSK plc (NYSE:GSK)

XML Financial LLC lessened its stake in GSK plc (NYSE:GSK) by 5.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 23,548 shares of the pharmaceutical company’s stock after selling 1,386 shares during the quarter. XML Financial LLC’s holdings in GSK were worth $796,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Eastern Bank acquired a new stake in GSK in the third quarter valued at $26,000. ST Germain D J Co. Inc. raised its holdings in shares of GSK by 195.5% in the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 522 shares during the period. Sunbelt Securities Inc. lifted its stake in GSK by 73.8% in the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after purchasing an additional 302 shares during the last quarter. Concord Wealth Partners grew its holdings in GSK by 231.8% during the third quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock worth $32,000 after purchasing an additional 547 shares during the period. Finally, Fortitude Family Office LLC acquired a new position in GSK during the third quarter worth approximately $42,000. 15.74% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on GSK. Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and decreased their price objective for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Finally, StockNews.com cut shares of GSK from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. Seven equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $43.25.

GSK Stock Down 1.0 %

GSK stock opened at $33.44 on Thursday. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.92. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. The stock has a market capitalization of $69.30 billion, a price-to-earnings ratio of 21.71, a PEG ratio of 1.47 and a beta of 0.63. The business’s fifty day moving average price is $33.93 and its two-hundred day moving average price is $37.90.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, January 9th. Shareholders of record on Friday, November 15th were paid a $0.3928 dividend. This is a boost from GSK’s previous quarterly dividend of $0.38. The ex-dividend date was Friday, November 15th. This represents a $1.57 annualized dividend and a yield of 4.70%. GSK’s payout ratio is 96.10%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.